Predictors of IOP reduction after SLT

The aim of this study was to identify predictors of intraocular pressure reduction following selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma, who are already taking maximally tolerated IOP-lowering medication and need further IOP reduction. In this prospective...

Retinoblastoma chemotherapeutic drugs and their toxic effects on RPE cells

There is reported clinical evidence of retinal pigment epithelium (RPE) alterations after intra-arterial (IAC) and intravitreal chemotherapy (IViC) of retinoblastoma. The purpose of this study was to investigate the cellular toxic effects of melphalan, topotecan and carboplatin on the RPE...

Rituximab as an immunosuppression treatment for thyroid eye disease

Thyroid eye disease is traditionally treated with high dose glucocorticosteroids and surgical orbital decompression, where responses are often inadequate. This medical treatment is centred around symptom control and reduction of thyroid hormone synthesis, not immunosuppression. Rituximab is an anti-CD20 monoclonal...

Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience

Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...

Management of diffuse OSSN with topical chemotherapy

Ocular surface squamous neoplasia (OSSN) can be localised to the conjunctiva or, less commonly, diffusely spread over the conjunctiva and cornea. Localised OSSN can be treated by surgical removal with adjuvant cryotherapy and chemotherapy with low rates of recurrence. Diffuse...

RaScaL Study

The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...

Brn3b neuroprotective effect in rat glaucoma model

An adeno-associated virus-directed overexpression of the Brn3b protein in hypothesised to confer neuroprotective effects in this paper. This is ultimately tested in a well-accepted rat glaucoma model (Morrison’s model: saline injection into episcleral veins of rat eyes with a force...

Long-term outcomes for hereditary retinoblastoma

Earlier diagnosis and more rigorous treatment regimens have contributed to better outcomes for patients with retinoblastoma. This study looked at 24 patients with hereditary bilateral retinoblastoma treated with systemic chemotherapy during a ten year period (2001-2011). The medical notes were...

Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN

Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly...

  • 1
  • 2 (current)